Conditional Approval and Emergency Use of Devices in China

1. Key takeaways

Conditional approval and emergency use are parallel regimes with different triggers, and treating them as one channel aims the file at the wrong test.

• Two regimes, two triggers. Article 19 of Decree 739 separates conditional approval for devices in urgent clinical need from emergency use for especially major public health emergencies or other events seriously threatening public health.
• The defining feature of conditional approval is that matters are stated in the registration certificate, and those statements are the legal source of later obligations.
• Conditional approval does not lighten the registrant duties. Under Article 20(1) of the regulation, the five obligations apply as they do elsewhere.
• Post-market evidence supplementation is the hidden cost. Some evidence accumulates after launch, and the product enters intensive post-market surveillance.
• Validity and renewal are unchanged. Under Article 22 the certificate runs for five years, and renewal must be applied for six months before expiry.
• Substantive post-market changes follow the variation route under Article 21 of the regulation and Article 79 of Order 47 (promulgated 26 August 2021, effective 1 October 2021); other changes are filed within 30 days.

2. Legal basis

Regulations on the Supervision and Administration of Medical Devices (State Council Decree No. 739, promulgated 9 February 2021, effective 1 June 2021)

• Article 14: seven categories of registration and filing material, the fourth being clinical evaluation material.
• Article 19: conditional approval and emergency use; where approval is conditional, the relevant matters must be stated in the certificate.
• Article 20(1): five registrant obligations covering the quality system, post-market research and risk control, adverse event monitoring and re-evaluation, traceability and recall.
• Article 20(2): the Chinese legal entity designated by an overseas registrant shall assist in performing those obligations.
• Article 21: substantive changes require a variation application; other changes require filing or reporting.
• Article 22: five-year validity; renewal six months before expiry; silence treated as approval; grounds for refusing a Class III renewal.

Provisions for the Administration of Medical Device Registration and Filing (SAMR Order No. 47, promulgated 26 August 2021, effective 1 October 2021)

• Article 10: special approval for innovative devices and priority approval for devices in urgent clinical need.
• Article 14(2): an overseas applicant or filer must designate a Chinese legal entity as agent, to assist with the Article 20(1) duties and with legal responsibility.
• Article 22: technical bodies shall establish a communication system.
• Article 41: deficiencies notified in full at one time, answered within one year, otherwise review is terminated and approval refused.
• Article 79: substantive changes require a variation; other changes are filed within 30 days; matters stated in the certificate fall within the variation scope.
• Article 107: failure to file leads to an order to correct and a fine of RMB 10,000 to RMB 30,000.

Normative and technical documents

• Announcement on Measures to Optimise Whole-Life-Cycle Supervision and Support High-End Device Innovation (No. 63 of 2025, issued 27 June 2025).
• Provisions on Instructions and Labels for Medical Devices (former CFDA Order No. 6, 2014): Articles 10 and 13 require imported instructions and labels to state the agent name, address and contact.
• Fees: domestic Class III initial registration RMB 153,600, variation RMB 50,400, renewal RMB 40,800; innovative device applications from small and micro enterprises are free.

Practical estimate. The situations for conditional approval and the framing of conditions follow Article 19 and current reviewing office requirements. The scope and duration of emergency use are set case by case, with no fixed figure. Provincial Class II fees differ, with some provinces publishing RMB 40,670 per registration unit.

3. Expert insights

The two regimes answer two different time mismatches. Article 19 can be read as a response to two kinds of timing problem.

The first is an approval form at product level; the second an emergency arrangement at event level. Mixing them sends the file the wrong way.

Statements in the certificate are the hinge of the regime. Article 19 requires the matters to be stated in the certificate, a requirement whose weight is often underestimated. Article 79 confirms the effect: stated matters fall within the variation scope, not the filing scope, so any adjustment requires a variation application with a full file and technical review. Three consequences follow: stated matters need their own register; a change touching them triggers a variation; and performance against them is a review focus at renewal.

Conditional approval is earlier launch with deferred evidence, not a lower standard. What changes is the distribution of evidence over time, not the total burden. The routine route requires everything before launch; conditional approval allows part to accumulate afterwards. Article 20(1) includes post-market research and a risk control plan, and that research is the main vehicle for completing the evidence. The structure is earlier launch, denser obligations, and the benefit calculation should include research, monitoring and reporting costs.

Conditional approval sits at a different layer from the two review channels. Special and priority approval under Article 10 of Order 47 are review channels affecting resource allocation and sequence. Conditional approval is an approval form affecting conditions and evidence timing. Emergency use is an emergency arrangement for a defined event.

The three can coexist: an urgent-need high-end device may enter through priority review and be approved on conditions.

For overseas registrants, the obligations run through the agent chain. Under Article 20(2) of the regulation and Article 14(2) of the order, an overseas registrant must designate a Chinese legal entity as agent to assist with the Article 20(1) duties. For such a product the chain matters more, because post-market research, monitoring, traceability and recall must run inside China, and an agent on paper leaves the conditions unimplemented. Articles 10 and 13 of Order No. 6 also require imported labels to state the agent name, address and contact.

Conditionally approved products iterate quickly: new indications, specifications, performance improvements. Each change must be classified as substantive or other, with the first requiring a variation and the second filed within 30 days; failure to file in time exposes the registrant to a fine of RMB 10,000 to RMB 30,000 under Article 107. The judgment is harder, because a change that would be a filing elsewhere becomes a variation if it touches a stated condition. The control is to put that question first on the change assessment form.

4. Practical recommendations

• Distinguish the regimes first, since the two require different files.
• Keep a register of stated conditions with performance status, owner and completion date.
• Include post-market research in the benefit calculation, alongside the earlier launch.
• Put the stated-condition question first on the change assessment form, ahead of the substantive change test (Article 21; Article 79).
• Give the agent real execution resources, with the authorisation setting out its role in post-market research, monitoring, traceability and recall (Article 20(2); Article 14(2)).
• Lock the renewal window early, applying six months before expiry under Article 22.

5. Verification checklist

• □ The regime is identified as conditional approval or emergency use (Article 19).
• □ Stated conditions are registered and confirmed as variation scope (Article 79).
• □ Post-market research and risk control plans are executable (Article 20(1)).
• □ Monitoring, re-evaluation, traceability and recall systems operate (Article 20(1)).
• □ Changes touching stated conditions are identified for variation; others are scheduled within 30 days (Article 79).
• □ A Chinese legal entity is agent, with assisting duties authorised (Article 14(2)).
• □ Imported labels state agent name, address and contact (Articles 10 and 13).
• □ The renewal date is locked at six months before expiry (Article 22).
• □ The response plan follows the one-year limit (Article 41).
• □ Fees follow RMB 153,600 initial, RMB 50,400 variation and RMB 40,800 renewal, with Class II verified provincially.
• □ Feedback on condition framing was sought through the communication channel (Article 22).
• □ The Article 107 fine exposure of RMB 10,000 to RMB 30,000 is in compliance guidance.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team manages NMPA Class II/III registrations and filing procedures, coordinates typetesting, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com